Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Universal Health Services (UHS)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
$196.46+10.91%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
24.02 → 23.26 EPS · FY ending Dec 31, 2027 · 12 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 12; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for UHS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Keep capital spending between $950M and $1.1B in 2026 | The company manages capital spending near $1 billion. | Under Pressure | capex exceeds $1.1B in FY26 | Capital expenditures: $214.942M FY2026-Q3; GAAP. Published target: $950M-$1.1B. Annual target cannot be compared with a quarterly or TTM observation. Oct 27, 2026214,942,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
UHS is a healthcare business with a growth-oriented, cyclical thesis rather than a clear turnaround. The thesis is intact, though recent momentum has weakened and management execution is volatile.
The valuation evidence describes UHS as cheap versus peers, with expectations below the model’s baseline and no signs of unusually fragile expectations. Confidence in that valuation assessment is medium, so the gap is a useful signal rather than a settled conclusion.
Near term, revenue growth is continuing, but UHS reported an earnings miss on October 27 and its momentum measure fell. Management has lowered its 2026 revenue outlook, while evidence of progress on investment commitments is limited; the broader sector backdrop remains supportive.
A guidance increase next quarter after the recent cut would signal a meaningful recovery in execution. Continued earnings strength from sector peers could support the backdrop, while further weakening in job growth could increase recession concerns and pressure cyclical businesses.
For the next one to three years, revenue growth and a supportive healthcare backdrop keep the thesis intact, but recent earnings weakness and volatile execution make follow-through the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| EPS stays strong near $23.4 per share. |
| Under Pressure |
| EPS falls below $21.5 in FY26 |
Diluted EPS: $5.22 per share FY2026-Q3; GAAP. Published target: >= $23.4. Annual target cannot be compared with a quarterly or TTM observation. Oct 27, 20265.22 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain stable management amid legal and leadership risks | A supporting condition in Universal Health Services's published investment case. The stated target is no major legal or leadership disruptions. | Intact | major legal rulings or executive departures hurt management | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue to about $18.6 billion in fiscal 2026 | UHS grows revenue about 6% a year to $18.6 billion in 2026. | Under Pressure | revenue falls below $17.3B in FY26 | Revenue: $4.733B FY2026-Q3; GAAP. Published target: ~$18.6B. Annual target cannot be compared with a quarterly or TTM observation. Oct 27, 20264,733,352,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$25.28 → $23.26 · observed estimates
$19.39B → $19.50B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $25.28 | $19,391,814,965 | 11 / 14 |
| 2026-07-25 | $25.16 | $19,398,038,920 | 13 / 17 |
| 2026-07-26 | $25.16 | $19,398,038,920 | 13 / 17 |
| 2026-07-27 | $25.16 | $19,398,038,920 | 13 / 17 |
| 2026-07-28 | $25.16 | $19,398,038,920 | 13 / 17 |
| 2026-07-29 | $24.74 | $19,483,080,262 | 11 / 14 |
| 2026-07-30 | $25.14 | $19,436,882,340 | 13 / 17 |
| 2026-07-31 | $24.44 | $19,515,502,942 | 11 / 14 |
| 2026-08-01 | $24.44 | $19,515,502,942 | 11 / 14 |
| 2026-08-02 | $24.19 | $19,501,877,420 | 14 / 17 |
| 2026-08-03 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-04 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-05 | $24.13 | $19,506,603,890 | 14 / 17 |
| 2026-08-06 | $24.13 | $19,506,603,890 | 14 / 17 |
| 2026-08-08 | $24.13 | $19,506,603,890 | 14 / 17 |
| 2026-08-09 | $24.13 | $19,506,603,890 | 14 / 17 |
| 2026-08-10 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-12 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-13 | $24.13 | $19,506,603,890 | 14 / 17 |
| 2026-08-14 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-15 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-16 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-17 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-18 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-19 | $24.19 | $19,521,659,609 | 11 / 14 |
| 2026-08-20 | $24.17 | $19,524,129,029 | 11 / 14 |
| 2026-08-21 | $24.09 | $19,524,129,029 | 11 / 14 |
| 2026-08-22 | $24.09 | $19,524,129,029 | 11 / 14 |
| 2026-08-23 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-24 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-25 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-26 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-27 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-28 | $24.09 | $19,524,129,029 | 12 / 14 |
| 2026-08-29 | $24.06 | $19,508,209,674 | 12 / 14 |
| 2026-08-30 | $24.06 | $19,486,579,001 | 12 / 14 |
| 2026-08-31 | $24.06 | $19,486,579,001 | 12 / 14 |
| 2026-09-01 | $24.06 | $19,486,579,001 | 12 / 14 |
| 2026-09-02 | $24.06 | $19,486,579,001 | 12 / 14 |
| 2026-09-03 | $24.06 | $19,486,579,001 | 12 / 14 |
| 2026-09-04 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-05 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-06 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-07 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-08 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-09 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-10 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-11 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-12 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-13 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-14 | $24.04 | $19,486,355,313 | 12 / 14 |
| 2026-09-15 | $23.96 | $19,486,355,313 | 12 / 14 |
| 2026-09-16 | $23.96 | $19,486,355,313 | 12 / 14 |
| 2026-09-17 | $23.96 | $19,486,355,313 | 12 / 14 |
| 2026-09-18 | $23.96 | $19,486,355,313 | 12 / 14 |
| 2026-09-19 | $23.96 | $19,486,355,313 | 12 / 14 |
| 2026-09-20 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-21 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-22 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-23 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-24 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-25 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-26 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-27 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-28 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-29 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-09-30 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-01 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-02 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-03 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-04 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-05 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-06 | $24.02 | $19,484,824,063 | 12 / 14 |
| 2026-10-07 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-08 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-09 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-10 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-11 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-12 | $23.99 | $19,482,817,313 | 12 / 14 |
| 2026-10-13 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-14 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-15 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-16 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-17 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-18 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-19 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-20 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-21 | $23.93 | $19,482,824,882 | 12 / 14 |
| 2026-10-22 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-23 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-24 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-25 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-26 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-27 | $23.92 | $19,482,824,882 | 12 / 14 |
| 2026-10-28 | $23.96 | $19,482,748,757 | 12 / 14 |
| 2026-10-29 | $23.52 | $19,478,949,395 | 11 / 13 |
| 2026-10-30 | $23.31 | $19,488,468,556 | 11 / 13 |
| 2026-10-31 | $23.31 | $19,488,468,556 | 11 / 13 |
| 2026-11-01 | $23.31 | $19,488,468,556 | 11 / 13 |
| 2026-11-02 | $23.31 | $19,488,468,556 | 11 / 13 |
| 2026-11-03 | $23.26 | $19,501,593,556 | 12 / 14 |
| 2026-11-04 | $23.26 | $19,501,593,556 | 12 / 14 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 13 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.